Please wait


.2


Revvity, Inc. and Subsidiaries
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS



The unaudited pro forma condensed consolidated financial statements presented herein have been prepared in accordance with Article 11 of Regulation S-X and are based upon the Company’s audited consolidated financial statements for the year ended December 28, 2025 and the unaudited consolidated financial statements for the six months ended July 5, 2026 and certain assumptions, as set forth in the notes to unaudited pro forma condensed consolidated financial statements, that the Company believes are reasonable. On July 31, 2026, the Company entered into a definitive agreement to divest its Immunodiagnostics business in China (“China IDX”). The unaudited pro forma condensed consolidated balance sheet is presented as if the sale had been completed on July 5, 2026 and the unaudited pro forma condensed consolidated statements of operations are presented as if the sale had been completed on December 30, 2024. The pro forma adjustments presented herein are based on estimates and certain information that is currently available and may change as additional information becomes available. The unaudited pro forma condensed consolidated financial statements are not necessarily indicative of the results of operations or the financial position that would have resulted had the sale of China IDX been completed at the beginning of or as of the periods presented, nor is it indicative of the results of operations in future periods or the future financial position of the Company.


Revvity, Inc. and Subsidiaries
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
AS OF JULY 5, 2026

(In thousands)HistoricalDisposition and Pro Forma AdjustmentsPro Forma
Current assets:
   Cash and cash equivalents $1,022,943 $8,166 (a), (b)$1,031,109 
   Accounts receivable, net709,175 (86,671)(a)622,504 
   Inventories, net378,502 (7,142)(a)371,360 
   Other current assets187,101 56,522 (a), (b)243,623 
         Total current assets2,297,721 (29,125)2,268,596 
Property, plant and equipment, net456,251 (14,173)(a)442,078 
Operating lease right-of-use assets, net150,945 (4,232)(a)146,713 
Intangible assets, net2,224,001 (127,675)(a)2,096,326 
Goodwill6,607,802 (35,000)(a)6,572,802 
Other assets, net309,114 44,794 (a), (b)353,908 
         Total assets$12,045,834 $(165,411)(a)$11,880,423 
Current liabilities:
   Current portion of long-term debt$572,156 $— $572,156 
   Accounts payable165,740 (3,679)(a)162,061 
   Accrued expenses and other current liabilities538,461 3,741 (a)542,202 
         Total current liabilities1,276,357 62 1,276,419 
Long-term debt2,633,094 $— 2,633,094 
Long-term liabilities771,359 (33,490)(a), (b)737,869 
Operating lease liabilities136,266 (2,915)(a)133,351 
         Total liabilities4,817,076 (36,343)4,780,733 
         Total stockholders' equity7,228,758 (129,068)(a), (b)7,099,690 
         Total liabilities and stockholders' equity$12,045,834 $(165,411)$11,880,423 
PREPARED IN ACCORDANCE WITH GAAP
        












Revvity, Inc. and Subsidiaries
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED INCOME STATEMENTS

Six Months Ended July 5, 2026Six Months Ended June 29, 2025
(In thousands, except per share data) HistoricalDisposition and Pro Forma AdjustmentsPro FormaHistoricalDisposition and Pro Forma AdjustmentsPro Forma
Revenue$1,440,806 $(42,785)(c)$1,398,021 $1,385,046 $(75,801)(c)$1,309,245 
Cost of revenue 636,285 (24,243)(c)612,042 616,944 (38,754)(c)578,190 
Selling, general and administrative expenses 532,458 (26,943)(c)505,515 498,245 8,904 (c), (d)507,149 
Research and development expenses 106,861 (177)106,684 106,867 — 106,867 
Operating income from continuing operations 165,202 8,578 173,780 162,990 (45,951)117,039 
Interest income (11,563)28 (c)(11,535)(18,426)31 (c)(18,395)
Interest expense 47,708 — 47,708 45,901 — 45,901 
Change in fair value of investments9,455 — 9,455 (1,118)— (1,118)
Other expense, net 6,079 488 (c)6,567 15,601 (1,305)(c)14,296 
Income from continuing operations, before income taxes 113,523 8,062 121,585 121,032 (44,677)76,355 
Provision for income taxes 19,149 (1,335)(c)17,814 24,141 (477)(c), (d)23,664 
Income from continuing operations 94,374 9,397 103,771 96,891 (44,200)52,691 
Loss from discontinued operations (1,836)— (1,836)(706)— (706)
Net income $92,538 $9,397 $101,935 $96,185 $(44,200)$51,985 
Diluted earnings per share:
Income from continuing operations $0.84 $0.93 $0.82 $0.44 
Loss from discontinued operations(0.02)(0.02)(0.01)(0.01)
Net income $0.82 $0.91 $0.81 $0.43 
Weighted average diluted shares of common stock outstanding111,746 111,746 118,882 118,882 
 ABOVE PREPARED IN ACCORDANCE WITH GAAP





Revvity, Inc. and Subsidiaries
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED INCOME STATEMENTS

Twelve Months Ended December 28, 2025
(In thousands, except per share data) HistoricalDisposition and Pro Forma AdjustmentsPro Forma
Revenue$2,856,051 $(164,552)(c)$2,691,499 
Cost of revenue 1,291,686 (99,558)(c)1,192,128 
Selling, general and administrative expenses 991,890 (26,688)(c), (d)965,202 
Research and development expenses 215,840 — 215,840 
Operating income from continuing operations 356,635 (38,306)318,329 
Interest income (31,103)76 (c)(31,027)
Interest expense 92,185 — 92,185 
Change in fair value of investments11,456 — 11,456 
Other expense, net 15,820 (2,765)(c)13,055 
Income from continuing operations, before income taxes 268,277 (35,617)232,660 
Provision for income taxes 28,394 2,307 (c), (d)30,701 
Income from continuing operations 239,883 (37,924)201,959 
Income from discontinued operations 1,318 — 1,318 
Net income $241,201 $(37,924)$203,277 
Diluted earnings per share:
Income from continuing operations $2.06 $1.73 
Income from discontinued operations0.01 0.01 
Net income $2.07 $1.74 
Weighted average diluted shares of common stock outstanding116,595 116,595 
 ABOVE PREPARED IN ACCORDANCE WITH GAAP





Revvity, Inc. and Subsidiaries
NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


1.Pro Forma Adjustments

(a) To eliminate all historical assets and liabilities of China IDX.
(b) To reflect a potential consideration from the sale of China IDX of $140 million, which includes certain liabilities to be transferred and excludes certain contingent consideration.
(c) To eliminate the historical revenues and expenses of China IDX.
(d) Includes the loss on the probable disposition of China IDX of $42 million, including tax impacts.